Cytokinetics Inc Licensing Collaboration And Royalty Monetization Deals With RTW Investments Focused To CK-274 Corporate Call Transcript
Good morning and welcome, ladies and gentlemen, to Cytokinetics' Conference Call. At this time, I would like to inform you that this call is being recorded. (Operator Instructions)
I will now turn the call over to Diane Weiser, Cytokinetics' Senior Vice President of Corporate Communications and Investor Relations. Please go ahead.
Good morning, everyone, and thanks for joining us on the call today. Robert Blum, our President and Chief Executive Officer, will lead us off today with an overview of today's announcement. Then Libby Schnieders, Senior Vice President of Business Development, will speak to the multiple components underlying the deal before Ching Jaw, our SVP and Chief Financial Officer, will summarize the financial terms of the deals and how they inform our financial outlook. Next, Fady Malik, our Executive Vice President of R&D, will discuss the impact of these transactions on the development program for CK-274 before Robert provides final comments and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |